Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.560
0.00 (0.00%)
Aug 17, 2026, 11:56 AM EDT - Market open

Aldeyra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-24.07-35.27-60.12-42.79-62.68-56.22
Net Income
-23.05-33.85-55.85-37.54-62.02-57.78
Earnings Per Share
-0.38-0.56-0.94-0.64-1.06-1.07
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
45.0970.04101.15142.82174.3104.79
Total Debt
0.1415.5315.315.6616.0815.86
Net Cash (Debt)
44.9554.5185.85127.17158.2288.93
Net Cash Growth
-32.27%-36.50%-32.49%-19.63%77.91%136.96%
Net Cash Per Share
0.750.911.442.162.711.65

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-22.02-33.35-43.21-30.33-56.64-42.56
Capital Expenditures
-0.02----0.02-0.01
Free Cash Flow
-22.04-33.35-43.21-30.33-56.65-42.56
Free Cash Flow Growth
------

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-16.3213.27---